MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Personalis Total Assets 2011-2026 | PSNL
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Personalis
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 270 M | 225 M | 293 M | 397 M | 245 M | 157 M | 41.7 M | 33.6 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 397 M | 33.6 M | 208 M |
Quarterly Total Assets Personalis
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 243 M | 259 M | 273 M | 270 M | 240 M | 186 M | 195 M | 225 M | 227 M | 249 M | 272 M | 293 M | 318 M | - | 381 M | 397 M | 407 M | 383 M | 396 M | 245 M | 245 M | 245 M | 245 M | 157 M | 157 M | 157 M | 157 M | 41.7 M | 41.7 M | 41.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 407 M | 41.7 M | 240 M |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 29.0 | -3.07 % | $ 316 M |  China |
 |
Brainsway Ltd.
BWAY
|
94.3 M | $ 23.87 | -0.13 % | $ 99.4 M |  Israel |
 |
Aspira Women's Health
AWH
|
17.4 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
76.7 M | $ 1.14 | -2.16 % | $ 1.45 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M | Israel |
 |
Celcuity
CELC
|
245 M | $ 104.95 | -1.72 % | $ 4.14 B | USA |
 |
Co-Diagnostics
CODX
|
95.3 M | - | - | $ 79.8 M | USA |
 |
Castle Biosciences
CSTL
|
531 M | $ 29.41 | -6.17 % | $ 817 M | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 202.21 | -0.11 % | $ 22.4 B | USA |
 |
Danaher Corporation
DHR
|
77.5 B | $ 210.56 | -0.33 % | $ 154 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
467 M | $ 18.83 | -5.23 % | $ 1.01 B | USA |
 |
DarioHealth Corp.
DRIO
|
96.4 M | $ 11.75 | 2.8 % | $ 333 M | Israel |
 |
DexCom
DXCM
|
6.34 B | $ 73.08 | 1.11 % | $ 28.5 B | USA |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 23.18 | -0.39 % | $ 701 M | USA |
 |
Exact Sciences Corporation
EXAS
|
5.86 B | $ 103.45 | 0.15 % | $ 19.5 B | USA |
 |
Guardant Health
GH
|
2.01 B | $ 103.36 | -2.84 % | $ 13 B | USA |
 |
Interpace Biosciences
IDXG
|
14.8 M | $ 1.85 | 2.78 % | $ 8.12 M | USA |
 |
QIAGEN N.V.
QGEN
|
5.69 B | - | - | $ 10.6 B |  Niderland |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
16.9 B | $ 99.61 | 1.22 % | $ 8.22 B |  Irlanda |
 |
Illumina
ILMN
|
6.3 B | $ 117.53 | -2.06 % | $ 18.7 B | USA |
 |
Charles River Laboratories International
CRL
|
7.14 B | $ 169.68 | 3.11 % | $ 8.41 B | USA |
 |
IDEXX Laboratories
IDXX
|
3.35 B | $ 635.6 | 0.77 % | $ 52.4 B | USA |
 |
IQVIA Holdings
IQV
|
29.9 B | $ 166.19 | -1.87 % | $ 28.6 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
29 B | $ 31.19 | 0.73 % | $ 20 B | Niderland |
 |
Lantheus Holdings
LNTH
|
1.98 B | $ 74.31 | 1.54 % | $ 5.14 B | USA |
|
Biodesix
BDSX
|
97.2 M | $ 13.26 | 4.0 % | $ 1.72 B | USA |
 |
Quidel Corporation
QDEL
|
1.87 B | $ 22.47 | -4.85 % | $ 947 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 283.38 | 0.32 % | $ 23.8 B | USA |
 |
Biomerica
BMRA
|
5.94 M | $ 2.17 | -2.25 % | $ 4.98 M | USA |
 |
Bioventus
BVS
|
811 M | $ 8.57 | -0.06 % | $ 537 M | USA |
 |
Medpace Holdings
MEDP
|
1.98 B | $ 452.99 | 1.47 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
3.71 B | $ 1 378.44 | 0.14 % | $ 28.4 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
1.03 B | $ 4.32 | -1.37 % | $ 391 M | USA |
 |
ENDRA Life Sciences
NDRA
|
4.45 M | $ 3.9 | 1.96 % | $ 2.09 M | USA |